CSF1R and benign prostatic hyperplasia: Pharmacological inhibition of RTK signaling with sunitinib, as well as CSF1R silencing or ligand neutralization, substantially reduced fibroblast-induced proliferative responses in vitro and suppressed prostate enlargement in an androgen-induced BPH mouse model.